ClinicalTrials.gg
Drug

Encorafenib clinical trials

Also written LGX818, Braftovi and ONO-7702.

studies test it
60
open now
11
in phase 3
7
first study started
2011

How each study uses encorafenib is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study

Get an email when these change. Save the encorafenib studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Get alerts for these studies
See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your alerts, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your alerts. Stop any time.

Approvals

The first approval found in each region, with its record

United States
27 Jun 2018 · BRAFTOVI · NDA 210496 (FDA, Drugs@FDA)
European Union
19 Sept 2018 · Braftovi · EMEA/H/C/004580 (EMA)

From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out

How studies write it

Studies that test it under each name

Name

Encorafenib
44
W0090
3

Brand

Braftovi
21

Development codes

LGX818
26
ONO-7702
4
PF-07263896
3

Studies by the year they started

60 studies that test it; most in 2021 (9)

Studies that test encorafenib, by start year
YearStudies
20111
20122
20134
20143
20152
20164
20184
20198
20208
20219
20225
20234
20244
20251
20261

By phase

A phase 1/2 study counts in both.

Early Phase 1
2
Phase 1
14
Phase 2
44
Phase 3
7
Phase 4
2
No phase
1

What it is tested for

Each study’s main condition, where its own words name it, so a study counts once.

Who runs them

Industry 26 · Other 34

Pfizer (17) · Pierre Fabre Medicament (5) · M.D. Anderson Cancer Center (4) · Array BioPharma (3) · Memorial Sloan Kettering Cancer Center (2) · Peter MacCallum Cancer Centre, Australia (2) · Intergroupe Francophone de Cancerologie Thoracique (1) · Alliance for Clinical Trials in Oncology (1)

Often tested with

Tested in the same studies.

Binimetinib (38) · Cetuximab (13) · Nivolumab (8) · Ribociclib (5) · Pembrolizumab (4) · Dabrafenib (3) · Trametinib (3) · Palbociclib (3)

Related medicines

As reviewed, each with the page that says it.

Coming up

From the study records. Dates are the sponsors’ own estimates and often move.

Reaching primary completion within a year · 8, 2 in phase 3

Studies that test encorafenib, phase 3 first.

Studies

Open first, then newest update. How each study uses encorafenib is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.

Testing it · 60

See all 60 studies that test encorafenib →

Given beside what is tested · 11 — encorafenib is usual care or a partner of the new treatment

Codes

What other systems call encorafenib · ClinicalTrials.gg INT000307

  • MeSH (NLM) C000601108encorafenibConfirmed ClinicalTrials.gov, NLM
  • UNII (FDA) 8L7891MRB6ENCORAFENIBConfirmed FDA, NLM, Wikidata
  • RxNorm 2049106Confirmed FDA, Wikidata
  • Wikidata Q15409405encorafenibConfirmed FDA, NLM, Wikidata
  • NCI Thesaurus C98283EncorafenibOne source FDA
  • DrugBank DB11718One source Wikidata

“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.